Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

NCI-COG Pediatric MATCH Trial: Treatment Determined by Tumor Targets

April 26, 2018 (Noon - 1:30 p.m. ET)

Sponsor/Co-Sponsor(s)

Obstetric and Pediatric Pharmacology and Therapeutics Branch (OPPTB), Best Pharmaceuticals for Children Act (BPCA), NICHD

Location

NIH Neuroscience Center Building, 6001 Executive Blvd, Room B1/B2, Rockville, MD

Purpose

Although research has improved outcomes for children and adolescents with cancer, challenges remain. Precision medicine trials for pediatric cancer patients are ongoing. Pediatric MATCH is a nationwide trial to explore whether targeted therapies are effective for children and adolescents with solid tumors that have specific genetic mutations. The National Cancer Institute (NCI) and the Children’s Oncology Group, a member of NCI’s National Clinical Trials Network, developed the trial with input from the Food and Drug Administration and pharmaceutical companies. The trial is the first pediatric precision medicine trial of this scale.

Nita Seibel, M.D., will discuss Pediatric Match and related research. She is a board-certified pediatric hematologist-oncologist and the head of NCI’s Pediatric Solid Tumor Therapeutics program.

Contact

George Giacoia, OPPTB, NICHD
Phone: (301) 496-5589
E-mail: giacoiag@mail.nih.gov

Please note: Views expressed during NICHD-sponsored events do not necessarily reflect the opinions or the official positions of NICHD, NIH, or HHS.